Results 131 to 140 of about 21,294 (218)

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement. [PDF]

Intern Med, 2023
Ijichi M, Fukuda Y, Kashima A, Sagara H.
europepmc   +1 more source

NPM/ALK rearrangements in indolent cutaneous lesions [PDF]

Leukemia, 1999
F, Hernández, O, López, C, Estivill, M, Baiget, R M, Pujol, R, Bordes, J F, Nomdedéu   +6 more
openaire   +2 more sources

State‐of‐the‐Art Strategies for Circular RNA in Cancers: Opportunity and Challenge

MedComm, Volume 7, Issue 2, February 2026.
Overview of circular RNA in tumors. ABSTRACT Circular RNAs (circRNAs) are characterized by their covalently closed structure, remarkable stability, and precise spatiotemporal regulation, evolving from once‐overlooked transcriptional byproducts to pivotal molecular regulators.
Zehao Ding, Zai Luo, Liao Zhang, Shaopeng Zhang, Renchao Zhang, Zhengjun Qiu, Chen Huang   +6 more
wiley   +1 more source

Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire. [PDF]

Drugs Real World Outcomes, 2023
Figueiredo A, Rodrigues A, Gaspar C, Felizardo M.   +3 more
europepmc   +1 more source

Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG‐TOP2 Study

Cancer Science, Volume 117, Issue 2, Page 522-535, February 2026.
In the JCCG‐TOP2 nationwide pediatric cancer genomic profiling study, 204 patients' tumors and peripheral blood from 50 institutions across Japan were successfully analyzed using a dual DNA/RNA panel. A total of 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%),
Kayoko Tao, Takako Yoshioka, Miho Kato, Kazuyuki Komatsu, Shinichi Tsujimoto, Kenichi Sakamoto, Kazuki Tanimura, Minako Sugiyama, Masahiro Sekiguchi, Yoshiko Nakano, Yoshihiro Otani, Yasushi Yatabe, Akihiko Yoshida, Hajime Okita, Junko Hirato, Kenichi Kohashi, Yukichi Tanaka, Shinji Kohsaka, Takashi Kubo, Kuniko Sunami, Makoto Hirata, Shuichi Tsutsumi, Hiroyuki Aburatani, Katsuyoshi Koh, Masahiro Hirayama, Shuhei Karakawa, Yukayo Terashita, Hiroyuki Fujisaki, Takeshi Yagi, Akihiro Yoneda, Shinji Mochizuki, Hiroyuki Shichino, Tatsuya Suzuki, Tetsuya Takimoto, Koichi Ichimura, Chitose Ogawa, Kimikazu Matsumoto, Hitoshi Ichikawa, Motohiro Kato   +38 more
wiley   +1 more source

Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44‐ALK Fusion: A Case Report and Literature Review

The Clinical Respiratory Journal
Neuroendocrine tumor (NET) is a deadly malignancy disease that can be found anywhere in the body. The lack of tumor‐specific treatment led to the worse prognosis of NET.
Haiyang Chen, Yingxi Wu, Xuan Wu, Kai Wang, Qingxin Xia, Qiming Wang   +5 more
doaj   +1 more source

EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report. [PDF]

Ann Transl Med, 2023
Chen D, Ma S, Sun L, Lang Y, Yang B.
europepmc   +1 more source

Optimal Detection of ALK Rearranged Lung Adenocarcinomas [PDF]

Journal of Thoracic Oncology, 2013
Karachaliou, Niki, Rosell, Rafael
openaire   +2 more sources

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.

Translational lung cancer research, 2015
Patients with non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements can derive significant clinical benefit from ALK tyrosine kinase inhibitor. Accurate patient identification is absolutely crucial for successful using ALK inhibitor treatment.
Hyojin, Kim, Jin-Haeng, Chung
openaire   +1 more source